AYTU press release
RTPR•17/11/2026•08:55 ET
0
Key Highlights
- ➤Aytu shareholders will receive $2.70 per share in Rosemont Pharmaceuticals’ tender offer
- ➤Ademi LLP is investigating whether the $2.70 purchase price reflects Aytu’s value
- ➤Investigation covers insider change-of-control benefits tied to the transaction
- ➤Investigation examines termination penalty restrictions on competing offers
Expert Statements
Guri Ademi, Attorney at Ademi LLP
“Ademi LLP would like to hear from you about the proposed acquisition and your rights as a shareholder.”
AYTU shareholders will receive just $2.70 per share in a tender offer transaction; Ademi LLP is investigating the deal price, benefits to company insiders, and restrictions on competing offers
MILWAUKEE (GlobeNewswire) -- Ademi LLP is investigating whether the proposed acquisition of Aytu (NASDAQ: AYTU) by Rosemont Pharmaceuticals, provides fair value to Aytu’s public shareholders and whether Aytu’s Board adequately protected shareholder interests in negotiating and approving the transaction.
Get started
Create a free account to read the full story.
